Table 2.

Molecular-targeted agents.

	Number of patients	Agent used	Dosage	Tolerability	Response	Median time to progression
Davids et al. [28]	n = 1  metastatic disease	Pazopanib	800 mg daily	Minimal adverse effects; dose reduction after gallstone pancreatitis to 400mg daily	After 2 months: CR of primary lesion, PR of metastatic lesions	4 months
Samlowski et al. [29]	n = 23  metastatic or unresectable disease	Imatinib	400 mg daily	Mainly Grade 1-2 toxicities; 3 episodes of Grade 4 toxicities; Grade 3 toxicities in 3 patients	no CR; PR: 4%	1-2 months
Di Bartolomeo et al. [30]	n = 58  metastatic disease (neuroendocrine tumors)	Octreotide	500 or 1000 micrograms 3 times a day	Carcinoid syndrome and abnormal urinary 5-hydroxy-indoloacetic acid excretion were reported	Median survival time of 22 months (range, 1–32+ months); PR: 3%	Disease stabilized for at least 6 months (range, 1–32+ months)
Meier et al. [31]	n = 1  locoregional disease	90Y-DOTATOC; targeted radiotherapy	85 mCi	Fatigue was main side effect	PR after 1 week; CR after 4 weeks	10 weeks until locoregional relapse
Fakiha et al. [32]	n = 1  clinically locoregional disease	Lanreotide	15 mg i.m. injection every two weeks	No side effects reported	Clinically CR after 2 months	7 months until relapse
Shah et al. [33]	n = 12  metastatic or regionally recurrent disease	Oblimersen sodium	7 mg per kilogram daily	Including Grade 3 and Grade 4 events, for example, lymphopenia, renal failure, cytopenia, and hyperkalemia	No responses; stable disease in 3 patients	PD in 9 patients

CR: complete response; PR: partial response; PD: progressive disease.